NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
Clinical Trials
24 trialsNCT04542369 2023-05-03
Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT00526396 2023-03-24
STAD-1
National Cancer Institute, Naples
Phase 3 Unknown
NCT05354700 2022-05-04
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2 Unknown
NCT03711305 2022-04-18
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT04740021 2021-02-05
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
Taizhou HoudeAoke Biomedical Co., Ltd.
Phase 2 Unknown
NCT02337712 2021-01-27
Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04696939 2021-01-06
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04683198 2020-12-24
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
ChineseAMS
Phase 2 Unknown
NCT03389087 2020-07-10
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT03585998 2020-03-02
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
Samsung Medical Center
Phase 2 Unknown
NCT03613597 2020-02-05
Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer
Guizhou Medical University
Phase 2 Unknown
NCT03700359 2019-11-29
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT03841136 2019-03-28
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
Fudan University
Phase 2 Unknown
NCT03781869 2018-12-20
Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase 2 Unknown
NCT03135977 2017-12-07
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT02348450 2016-12-05
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 4 Unknown
NCT02738346 2016-04-25
CBPC
University Hospital, Angers
Phase 3 Unknown
NCT00003284 2014-01-06
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01555710 2013-05-21
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
Alaunos Therapeutics
Phase 3 Unknown
NCT00168896 2006-02-14
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Charite University, Berlin, Germany
Phase 2/3 Unknown